Disease | N. SNPs d | DSI v | DPI v | Chr | Position | Consequence | Alleles | Class | AFEXOME | AFGENOME | Score vda | EI vda | N. PMIDs | First Ref. | Last Ref. | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ADRENOCORTICAL CARCINOMA, HEREDITARY
|
7 | 0.554 | 0.600 | 17 | 7673802 | missense variant | C/A;G;T | snv | 4.0E-06; 1.6E-05 | 0.700 | 0 | ||||||||
BASAL CELL CARCINOMA, SUSCEPTIBILITY TO, 7
|
7 | 0.554 | 0.600 | 17 | 7673802 | missense variant | C/A;G;T | snv | 4.0E-06; 1.6E-05 | 0.700 | 0 | ||||||||
Choroid Plexus Papilloma
|
17 | 0.554 | 0.600 | 17 | 7673802 | missense variant | C/A;G;T | snv | 4.0E-06; 1.6E-05 | 0.700 | 0 | ||||||||
GLIOMA SUSCEPTIBILITY 1
|
14 | 0.554 | 0.600 | 17 | 7673802 | missense variant | C/A;G;T | snv | 4.0E-06; 1.6E-05 | 0.700 | 0 | ||||||||
Nasopharyngeal carcinoma
|
320 | 0.554 | 0.600 | 17 | 7673802 | missense variant | C/A;G;T | snv | 4.0E-06; 1.6E-05 | 0.700 | 0 | ||||||||
ovarian neoplasm
|
757 | 0.554 | 0.600 | 17 | 7673802 | missense variant | C/A;G;T | snv | 4.0E-06; 1.6E-05 | 0.700 | 0 | ||||||||
Pancreatic carcinoma
|
322 | 0.554 | 0.600 | 17 | 7673802 | missense variant | C/A;G;T | snv | 4.0E-06; 1.6E-05 | 0.700 | 0 | ||||||||
Li-Fraumeni Syndrome
|
206 | 0.554 | 0.600 | 17 | 7673802 | missense variant | C/A;G;T | snv | 4.0E-06; 1.6E-05 | 0.820 | 1.000 | 38 | 1990 | 2018 | |||||
LI-FRAUMENI SYNDROME 1
|
39 | 0.554 | 0.600 | 17 | 7673802 | missense variant | C/A;G;T | snv | 4.0E-06; 1.6E-05 | 0.700 | 1.000 | 14 | 1992 | 2016 | |||||
Adult T-Cell Lymphoma/Leukemia
|
11 | 0.554 | 0.600 | 17 | 7673802 | missense variant | C/A;G;T | snv | 4.0E-06; 1.6E-05 | 0.010 | 1.000 | 1 | 1992 | 1992 | |||||
Leukemia, T-Cell
|
10 | 0.554 | 0.600 | 17 | 7673802 | missense variant | C/A;G;T | snv | 4.0E-06; 1.6E-05 | 0.010 | 1.000 | 1 | 1992 | 1992 | |||||
Malignant Neoplasms
|
1641 | 0.554 | 0.600 | 17 | 7673802 | missense variant | C/A;G;T | snv | 4.0E-06; 1.6E-05 | 0.100 | 0.923 | 13 | 1993 | 2019 | |||||
Carcinoma of lung
|
1204 | 0.554 | 0.600 | 17 | 7673802 | missense variant | C/A;G;T | snv | 4.0E-06; 1.6E-05 | 0.030 | 0.667 | 3 | 1993 | 2019 | |||||
Malignant neoplasm of lung
|
1142 | 0.554 | 0.600 | 17 | 7673802 | missense variant | C/A;G;T | snv | 4.0E-06; 1.6E-05 | 0.030 | 0.667 | 3 | 1993 | 2019 | |||||
Primary malignant neoplasm of lung
|
981 | 0.554 | 0.600 | 17 | 7673802 | missense variant | C/A;G;T | snv | 4.0E-06; 1.6E-05 | 0.030 | 0.667 | 3 | 1993 | 2019 | |||||
Neoplasms
|
1644 | 0.554 | 0.600 | 17 | 7673802 | missense variant | C/A;G;T | snv | 4.0E-06; 1.6E-05 | 0.780 | 1.000 | 9 | 1995 | 2020 | |||||
Xeroderma Pigmentosum, Complementation Group D
|
111 | 0.554 | 0.600 | 17 | 7673802 | missense variant | C/A;G;T | snv | 4.0E-06; 1.6E-05 | 0.010 | 1.000 | 1 | 1995 | 1995 | |||||
Adult Rhabdomyosarcoma
|
12 | 0.554 | 0.600 | 17 | 7673802 | missense variant | C/A;G;T | snv | 4.0E-06; 1.6E-05 | 0.020 | 1.000 | 2 | 1997 | 2011 | |||||
Childhood Rhabdomyosarcoma
|
12 | 0.554 | 0.600 | 17 | 7673802 | missense variant | C/A;G;T | snv | 4.0E-06; 1.6E-05 | 0.020 | 1.000 | 2 | 1997 | 2011 | |||||
Rhabdomyosarcoma
|
20 | 0.554 | 0.600 | 17 | 7673802 | missense variant | C/A;G;T | snv | 4.0E-06; 1.6E-05 | 0.020 | 1.000 | 2 | 1997 | 2011 | |||||
Caffeine related disorders
|
56 | 0.554 | 0.600 | 17 | 7673802 | missense variant | C/A;G;T | snv | 4.0E-06; 1.6E-05 | 0.010 | 1.000 | 1 | 1997 | 1997 | |||||
Mammary Neoplasms
|
385 | 0.554 | 0.600 | 17 | 7673802 | missense variant | C/A;G;T | snv | 4.0E-06; 1.6E-05 | 0.700 | 1.000 | 3 | 1998 | 2016 | |||||
Neoplastic Syndromes, Hereditary
|
6387 | 0.554 | 0.600 | 17 | 7673802 | missense variant | C/A;G;T | snv | 4.0E-06; 1.6E-05 | 0.700 | 1.000 | 9 | 2000 | 2017 | |||||
Carcinoma of bladder
|
309 | 0.554 | 0.600 | 17 | 7673802 | missense variant | C/A;G;T | snv | 4.0E-06; 1.6E-05 | 0.010 | 1.000 | 1 | 2001 | 2001 | |||||
Primary malignant neoplasm
|
1374 | 0.554 | 0.600 | 17 | 7673802 | missense variant | C/A;G;T | snv | 4.0E-06; 1.6E-05 | 0.100 | 1.000 | 12 | 2005 | 2019 |